Angela Rago

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

Gabriella Tomei, Sonia Morè, Francesca Di Landro, Velia Bongarzoni et autres

Abstract Multiple Myeloma (MM) is often diagnosed in patients (pts) aged > 75 years. These very elderly subjects are under-represented in clinical controlled trials, with a diagnostic work-up reduced in comparison to younger pts, especially from a biologic point of view. In …

it (code pays fourni par la source)

HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies”

Angela Rago, Lorenzo Ridola, Tommaso Caravita di Toritto

HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs.Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological …

it (code pays fourni par la source)

Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients

Sonia Morè, Massimo Offidani, Laura Corvatta, Silvia Aloisi et autres

We retrospectively analysed cytogenetics by fluorescence in situ hybridization (FISH) in 1.026 patients with multiple myeloma treated in real-world with the aim to establish its role in daily clinical practice. Thirty-seven percent of patients had no FISH data available. Based on median …

it, my (code pays fourni par la source)

Infection Events in Patients With Newly Diagnosed Multiple Myeloma With Anti-cd38 Monoclonal Antibody-based First Line Regimens: A Multicentric Italian Experience

Angela Rago, Francesca Fioritoni, Carmine Liberatore, Stefano Pulini et autres

it (code pays fourni par la source)

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients

Enrica Antonia Martino, Salvatore Palmieri, Mónica Galli, Daniele Derudas et autres

Background Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free …

it (code pays fourni par la source)

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi et autres

: Not available.

it, jp, us (code pays fourni par la source)

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi et autres

This preliminary study investigates the real-world efficacy and safety of Isatuximab (Isa) combined with pomalidomide (P) and dexamethasone (d) (IsaPd) as a salvage therapy for relapsed/refractory multiple myeloma (RRMM) patients treated outside of controlled clinical trials according to marketing approval. A cohort …

it (code pays fourni par la source)

Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study

Alessandra Vergori, Giulia Matusali, Eleonora Cimini, Licia Bordi et autres

Objective. We aimed to report the real-world use and outcomes over time in immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP). Methods. This observational study included participants who received T/C PrEP, categorized into three groups: (i) No COVID-19 (NoC), i.e., participants who …

it (code pays fourni par la source)

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials

Enrica Antonia Martino, Salvatore Palmieri, Mónica Galli, Daniele Derudas et autres

The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome …

it (code pays fourni par la source)

Real world use of Tixagevimab/Cilgavimab pre-exposure prophylaxis of COVID-19 in immunocompromised individuals: data from the OCTOPUS study.

Alessandra Vergori, Giulia Matusali, Eleonora Cimini, Licia Bordi et autres

We report real world use over time in immunocompromised subjects receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP). Observational study on participants receiving T/C PrEP stratified: never had COVID-19 (NoC), hybrids (H) and breakthrough infections (BTIs) if COVID-19 before or after PrEP, respectively. Anti-RBD …

it (code pays fourni par la source)

Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group

Francesca Fazio, Mauro Passucci, Jacopo Micozzi, Francesca Di Landro et autres

High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been considered the standard of therapy for younger fit patients with newly diagnosed multiple myeloma (MM), since several randomized trials demonstrated a survival benefit for ASCT compared to conventional chemotherapy, even …

it (code pays fourni par la source)

Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial

Maria Gabriella Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, Valerio De Stefano et autres

ABSTRACT: A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly …

it, au (code pays fourni par la source)